Bone metastasis is a common event in prostate cancer, and it is known that some of the bone morphogenetic proteins (BMPs) are expressed in prostate cancer cells, while no study on the expression of their receptors, BMPRs, has been reported. Here we report cloning and sequence analysis of the human BMPR-IB cDNA. We also analysed the expression of transcripts of three types of the BMPR genes in human tissues and prostate cancer cell lines. The BMPR-IB mRNA was present in various organs, but the highest level was found in the prostate. Moreover, the amount of BMPR-IB mRNA was signi®cantly low in prostate cancer tissues after androgen withdrawal and was also low in prostate cancer cell lines. RT ± PCR analysis showed that the BMPR-IB message was upregulated by androgen stimulation in the LNCaP cell line which expresses the androgen receptor. By contrast, the mRNA levels of BMPR-IA and BMPR-II were not signi®cantly dierent among non-cancerous and cancerous prostate tissues. It was also suggested that human BMPR-IA and BMPR-IB might have dierent biological functions in the prostate, although their sequences were 85.3% identical in the serine-threonine kinase domain.
Prostate cancer is one of the most common malignancies in men, and the incidence is increasing especially in developed countries, where the elderly population is rapidly expanding. For example, the death rate of prostate cancer soared in Japan from 1.7 in 1970 to 7.0 in 1993 per 100 000 population (Statistics and Information Department, 1995) . For over 50 years, androgen ablation has been the standard treatment for metastasized prostate cancer. In most of the cases, however, prostate cancer cells eventually lose androgen dependency during the progression to malignant stages, and the tumor cells resistant to endocrine therapy come to dominate. At that stage, the disease is often refractory to any therapeutic modalities (Dawson, 1993) . Characteristically, the most favored metastatic site of the prostate cancer is bone, where it stimulates new bone formation.
Bone morphogenetic proteins (BMPs) are members of the TGF-b superfamily and were originally identi®ed from extracts of bone by their capacity to induce ectopic bone formation in vivo (Urist, 1965; Urist et al. 1973) . To date, nine dierent types of BMPs have been identi®ed from various sources (Wozney et al., 1988; Celeste et al., 1990; O È zkaynak et al., 1990 . BMPs stimulate alkaline phosphatase activity and collagen synthesis in osteoblasts and proteoglycan synthesis in chondroblasts (Vukicevic et al., 1989) . In addition to those functions as a possible bone-inducing factor, BMPs have been shown to play signaling roles during vertebrate organogenesis (Niswander and Martin, 1993; Dudley et al., 1995; Winnier et al., 1995) . Thus, BMPs may constitute another example of a growth/differentiation factor family which shows a diverse function depending on the target cells and the stage of development. Although the BMP-2 and -4 mRNAs were detected in the normal and cancerous prostate tissues and in the prostate cancer cell lines, it remains to be elucidated if BMPs are actually involved in the osteogenic metastasis of the prostate cancer in vivo (Bentley et al., 1992; Harris et al., 1994) .
Recently, the BMP receptor (BMPR) family was identi®ed as transmembrane serine-threonine kinase receptors including two type I receptors (IA and IB) (ten Dijke et al., 1993 (ten Dijke et al., , 1994a and one type II receptor (Rosenzweig et al., 1995; Liu et al., 1995; Nohno et al., 1995) . At least the the BMP-2, -4 and -7 have been shown to bind to BMPRs (ten Dijke et al., 1994b; Koenig et al., 1994) . Eective ligand binding and signal transduction of BMPs are dependent on the optimal cooperation of one of the two type I receptors with the single type II receptor, which together form the necessary heterodimeric receptor complexes (Rosenzweig et al., 1995; Liu et al., 1995; Nohno et al., 1995) . Recently, it has been shown that expression of the dominant negative molecule of BMPR-IB in chicken embryonic hind limbs, but not the dominant negative BMPR-IA, greatly reduced interdigital apoptosis (Zou and Niswander, 1996) . Thus, although the primary amino acid sequence and ligand speci®city are similar for the BMPR-IA and BMPR-IB, they may have dierent signaling potentials and biological functions. Among the three BMPR molecules, BMPR-IB has not yet been cloned for humans. In this article, we report the results of cloning and sequence analysis of the human BMPR-IB cDNA. We report here for the ®rst time the expression of the three BMPR mRNAs in normal and cancerous prostatic tissues and in prostate cancer cell lines.
By reverse-transcription polymerase chain reaction (RT ± PCR) using degenerated primers P1 (sense), 5'-AT (ACT) GC (ACGT) AA (AG)CA(AG)AT(ACT)CA-(AG)ATG-3', and P2 (antisense), 5'-TA(AGT)AT(AG)-TC(ACGT)GCCAT(AGT)AT(AG)TA-3' (Figure 1 ), we obtained a cDNA fragment of human BMPR-IB from the cDNA pool of surgical specimens of gastric cancer. These primers were designed to amplify an approximately 600 bp fragment of the well-conserved serine-threonine kinase region of the TGF-b receptor family. To clone the 5' cDNA sequence of human BMPR-IB, Rapid Ampli®cation of cDNA Ends (RACE) method was performed using two speci®c primers P3, 5'-AGAACACTTTCACAGCTACC-3', and P4, 5'-ACTTTCCCATCCAAACTTCC-3'. To clone the 3'-end of the human BMPR-IB cDNA, a random-primed human normal prostate lgt10 cDNA library was screened by the cDNA selection method (Sasaki et al., in preparation) . Brie¯y, the method is based upon hybridization of the biotinylated probes with cDNA in the liquid phase and subsequent capture of the hybrids on streptavidine-coated magnetic beads. The selected cDNA clones were ampli®ed by PCR. By repeating this procedure twice, we could eciently concentrate the cDNAs containing the human BMPR-IB, so that the random pick-up enabled the identification of the clone.
The human BMPR-IB nucleotide sequence and its deduced amino acid sequence are shown in Figure 1 . An ATG codon (nucleotides 19 ± 21) ®tting the rules for the translational initiation (Kozak, 1987) and a stop codon (nucleotides 1525 ± 1527) were found at positions expected from the mouse BMPR-IB sequence. The entire open reading frame of the 1506 nucleotides encodes a 502 amino acid human BMPR-IB protein, which has a single hydrophobic transmembrane region and intracellular serine-threonine kinase domain (reviewed in ten Dijke et al., 1994c) . When the deduced amino acid sequence of human BMPR-IB was compared with those of other BMPRs, ten cystein residues were well-conserved in the extracellular domain ( Figure 2 ). In the extracellular domain, human BMPR-IB showed 42.1% amino acid identity with human BMPR-IA. It has been reported that the two type I BMPRs showed similar ligand speci®city, but their binding anity as a heterodimer with BMPR-II was dierent at least for BMP-2, -4 and BMP-7 (Rosenzweig et al., 1995; Liu et al., 1995; Nohno et al., 1995) .
In the intracellular serine-threonine kinase domain, the amino acid sequence identity of human BMPR-IB is 85.3% with human BMPR-IA but only 39.9% with human BMPR-II. The consensus sequence for the ATP binding was found in the kinase domains in the three human BMPRs (ten Dijke et al., 1993; Rosenzweig et al., 1995) . Following the kinase domain, the two type I BMPRs have homologous and short carboxyl tails of 5 amino acids. The total amino acid sequence identity of human and mouse BMPR-IB was 98.4%.
The expression of BMPR-IB in various human adult tissues was determined by RNA blot analysis on 2 mg of poly(A) + RNA. The human BMPR-IB cDNA fragment spanning nucleotides 1 ± 685, which corresponds to the 5' non-coding region and the extracellular domain, was used as a BMPR-IB speci®c probe. In this RNA blot analysis, one major transcript of about 6.5 kb was detected in the heart, brain, skeletal muscle, pancreas, thymus, prostate, testis, uterus and small intestine. A lower amount of the mRNA was found in the placenta, kidney, spleen and colon. In the skeletal muscle, prostate and testis, two additional minor bands of about 4.0 kb and 2.4 kb were detected (Figure 3) . We have not yet completely excluded the possibility that the 4.0 kb band represents cross-hybridization to 28S ribosomal RNA. Although the BMPR-IB mRNA was present in various human tissues, the highest amounts of the mRNA were found in the prostate. In mouse, it was reported that the BMPR-IB transcript was detected in the brain and much smaller amounts in the lung (ten Dijke et al., 1994a), but not in the other major organs. In that report, the prostate was not analysed. It is not known if the apparent discrepancy of the BMPR-IB expression is due to the species dierence or due to a higher sensitivity of our RNA blot analysis.
On the other hand, the level of the human BMPR-IA mRNA was reported to be high in the skeletal muscle and moderate in the heart, placenta, kidney and pancreas (ten Dijke et al., 1993) . In that study, too, the prostate was not examined for the BMPR-IA mRNA level. The transcript of the other member of human BMPR, BMPR-II, was ubiquitous in tissue distribution, including the prostate. (Rosenzweig et al., 1995; Figure 2 Comparison of the deduced amino acid sequence of human BMPR-IB with those of mouse BMPR-IB (ten Dijke, 1994a ) and human BMPR-IA (ten Dijke, 1993) . The conserved cystein residues in the extracellular domains are boxed. The transmembrane regions are overlined. The borders of the kinase domains are indicated by arrows, and the consensus ATP-binding sites are underlined. Identical amino acid residues are indicated by asterisks Expression of human BMPRs in prostate cancer H Ide et al Nohno et al., 1995) . Thus, the expression of three BMPRs may be regulated dierently among dierent tissues, which suggests a functional diversity of the three BMPRs in vivo.
To compare the levels of BMPR mRNAs in prostate cancer cells with those in the normal prostate, total RNAs were extracted form four human prostate cancer cell lines (LNCaP, TSU-PR1, PC-3, and DU-145) and from surgical specimens of normal human prostate and prostate cancer. Normal prostates were obtained from three patients who underwent total cystectomy for bladder cancer without evidence of invasion into the prostate. A careful pathological examination excluded the possibility of latent prostate cancer in these normal prostate tissues. All patients with the prostate cancer were treated previously with some kind of endocrine therapy before total prostatectomy. The cancerous part in the prostate tissue was separated macroscopically by an experienced pathologist for RNA extraction.
In order to minimize cross-hybridization, probes of human BMPR±IA and BMPR-II were made by nested RT ± PCR from skeletal and fetal lung poly (A) + RNAs (Clontech), respectively, using speci®c primers designed in the 5'-regions, the homology of which is low among the TGF-b receptor family. The speci®c probe for human BMPR-IA corresponds to the nucleotides 71 ± 833 of the BMPR-IA cDNA (ten Dijke et al., 1993) , and that for BMPR-II spans nucleotides 93 ± 601 of the BMPR-II cDNA (Rosenzweig et al., 1995) . The human BMPR-IB-speci®c probe was the 5' cDNA fragment described above.
Hybridization to the 32 P-labeled probes was performed under a standard high stringency condition (Figure 3) .
Under this condition, two major transcripts of about 7.5 kb and 4.4 kb, as well as one minor transcript of about 9 kb, were detected in the prostate by the human BMPR-IA probe; four distinct transcripts with about 7 kb, 6 kb, 4 kb and a size exceeding 10 kb were detected with the human BMPR-II probe in RNA from the prostate (Figure 4) . For BMPR-IA and BMPR-II, there was no signi®cant dierence in the amounts of mRNAs between the cancerous and noncancerous prostatic tissues. The levels of BMPR-IA and BMPR-II mRNA in the prostate cancer cell lines were also similar to those in the tissue specimens.
By contrast, the amount of BMPR-IB mRNA was signi®cantly lower in all the prostate cancer tissues after androgen withdrawal and in all the four prostate cancer cell lines examined, as compared to those in the normal prostate tissues. Because most of prostate cancers arise RNA blot analysis of BMPR-IB, BMPR-IA and BMPR-II on non-cancerous and cancerous prostate tissues and prostate cancer cell lines. LNCaP, PC-3 and TSU-PR1 cells were maintained in RPMI 1640 supplemented with 10% FBS, while DU-145 cells were cultured in Dulbecco's modi®ed Eagle's medium with 10% FBS. Samples: 1 ± 9, 20 mg of total RNA extracted from the cancer-bearing prostate tissues. N, noncancerous part. T, cancerous part; 10 ± 12, 20 mg of total RNA from the normal prostate tissues dissected for parenchymal (a) and peri-urethral (b) parts; 13, 2 mg of poly (A) + RNA of normal prostate (Clontech). For prostate cancer cell lines, 20 mg of total RNA was analysed. The hybridization was performed under the high-stringency condition described in the legend to Figure 3 , and the ®lters were then exposed for 5 days from the parenchymal portion, the expression of BMPRs was examined separately for the parenchymal and periurethral tissues of the normal prostate; no signi®cant dierence was noted between the two portions of the prostate (Figure 4, lanes 10 and 11) .
Because all of the prostate cancer patients were treated with some endocrine therapy before total prostatectomy, it is possible that the withdrawal of androgen caused down regulation of the BMPR-IB transcripts. Indeed, the amount of the BMPR-IB mRNA in the non-cancerous portion of the prostate was decreased to a level similar to those in the cancerous portion of the same prostate gland ( Figure  4 , samples 2, 6, 7). In the prostate cancer cell lines, the BMPR-IB mRNA was present but apparently at a lower level than that in normal prostate tissues. The presence of the BMPR-IB mRNA was further con®rmed by RT ± PCR analysis on PC-3 and LNCaP cell lines using four dierent sets of speci®c primers for BMPR-IB. A single band of the expected size was detected by each primer set, and the direct sequencing of the excised bands con®rmed that they were authentic BMPR-IB cDNA fragments (data not shown). Androgen dependence of the BMPR-IB mRNA expression was shown by RT±PCR analysis using LNCaP cell line which expresses androgen receptor (Tilley et al., 1990 ; our own data not shown). The RT ± PCR reaction in the exponentially amplifying cycle allowed semi-quantitative comparison of the mRNA expression. Figure 5 showed that the BMPR-IB message was upregulated, when the 1 nM synthetic androgen R1881 was added to the medium containing steroid-depleted serum (CS). It is possible that, among the three BMPRs, the amount of the BMPR-IB transcripts in the prostate is regulated uniquely by androgen, and the speci®c down regulation of BMPR-IB was induced in the cancerbearing prostatic glands by androgen withdrawal.
In situ expression analysis is required to determine which cells express BMPR-IB in vivo. For instance, it is conceivable that the BMPR-IB mRNA, but not BMPR-IA or BMPR-II mRNA, is present at a higher level in the prostate stromal cells than in the prostate epithelial cells, and BMPR-IB in the stromal cells is androgen-dependent. Alternatively, the prostatic cancer cells may secrete some paracrine factor which decreases the amount of the BMPR-IB mRNA in the surrounding non-cancerous prostate tissues.
In conclusion, we cloned and sequenced the cDNA of the human BMPR-IB, a receptor serine-threonine kinase which belongs to the TGF-b receptor superfamily. Unlike BMPR-II, BMPR-IB expression was characteristically high in the prostate among various normal human adult tissues. While the levels of expression of BMPR-IA and BMPR-II were similar among the cancerous and non-cancerous prostate tissues, BMPR-IB expression was signi®cantly low in cancer-bearing prostate glands after androgen withdrawal and also in the prostate cancer cell lines. These results suggest that the two human type I BMPRs, BMPR-IA and BMPR-IB, are under dierent transcriptional regulation and have dierent biological functions. Further study is required to elucidate the functional signi®cance of the down regulation of BMPR-IB in the prostatic cancer cell growth and its possible implication in therapy. ¨¨ F igure 5 LNCaP cells were grown for a period of 7 days in RPMI containing 10% dextran-charcoal treated serum (CS), which is steroid-depleted (Sigma). The synthetic androgen R1881 (New England Nuclear) was then added to a ®nal concentration of 1 nM and 24 h later, RNA was isolated. Twenty mg of total RNA from LNCaP cells treated with androgen or with CS alone was reverse-transcribed by random hexamer (pd(N) 6 ) and SuperScript reverse transcriptase (Life Technologies, Inc.). The cDNA was subjected to PCR for 10 to 35 cycles using the two sets of primers: human BMPR-IB, 5'-GCAGCACAGACGGA-TATTGT-3' (sense) and 5'-TTTCATGCCTCATCAACACT-3' (antisense); b-actin, 5'-GACTACCTCATGAAGATCCT-3' (sense) and 5'-GCGGATGTCCACGTCACACT-3' (antisense). The thermal-cycle pro®le was 45 s at 958C, 1 min at 608C and 1 min 30 s at 728C
